共识报告:粪菌移植——临床应用与操作流程
该共识由欧洲多国知名专家通过改良德尔菲法制定,采用GRADE系统评级证据与一致度,一致定义为至少75%作者同意。关键推荐包括:复发性艰难梭菌感染(至少两次标准治疗未获持续治愈)可使用粪菌移植;重度及重度复杂艰难梭菌感染在抗菌治疗早期失败时可考虑粪菌移植作为全结肠切除术的替代;炎症性肠病、肠易激综合征和代谢综合征的粪菌移植仅应在研究环境中进行。
要点
- 复发性艰难梭菌感染(至少两次标准治疗未获持续治愈)推荐使用粪菌移植。
- 重度及重度复杂艰难梭菌感染抗菌治疗早期失败时,可考虑粪菌移植替代全结肠切除术。
- 炎症性肠病、肠易激综合征和代谢综合征的粪菌移植仅应在研究环境中进行。
核心结论
- 粪菌移植或转移是治疗多种肠道菌群失调疾病的有前景的方法。
- 对于艰难梭菌感染以外的适应症,在作出更具体的推荐之前需要更多证据。
研究设计与样本
- 由欧洲多国知名专家参与,经文献回顾后通过反复传阅声明和完整稿件并间歇根据评论修改达成共识(采用改良德尔菲法)。
- 证据水平和一致度按GRADE系统评级,一致事先定义为至少75%的作者同意。
主要发现
- 关键推荐包括在复发性艰难梭菌感染(特征为至少两次既往标准治疗未获持续治愈)中使用粪菌移植。
- 在重度及重度复杂艰难梭菌感染中,若抗菌治疗早期失败,可考虑粪菌移植作为全结肠切除术的替代。
- 炎症性肠病、肠易激综合征和代谢综合征的粪菌移植仅应在研究环境中进行。
关键数值与推荐
- 复发性艰难梭菌感染:至少两次既往标准治疗未获持续治愈,推荐使用粪菌移植。
- 重度及重度复杂艰难梭菌感染:抗菌治疗早期失败时,可考虑粪菌移植替代全结肠切除术。
- 炎症性肠病、肠易激综合征和代谢综合征:粪菌移植仅应在研究环境中进行。
临床怎么用
- 原文未据此给出推荐。
局限性
- 除艰难梭菌感染外,评估粪菌移植用于其他疾病的对照或随机研究发表不多,使临床医生难以决定合适的适应症。
- 对于艰难梭菌感染以外的适应症,在作出更具体的推荐之前需要更多证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Faecal microbiota transplantation or transfer (FMT) aims at replacing or reinforcing the gut microbiota of a patient with the microbiota from a healthy donor. Not many controlled or randomised studies have been published evaluating the use of FMT for other diseases than Clostridium difficile infection, making it difficult for clinicians to decide on a suitable indication. AIM: To provide an expert consensus on current clinical indications, applications and methodological aspects of FMT. METHODS: Well-acknowledged experts from various countries in Europe have contributed to this article. After literature review, consensus has been achieved by repetitive circulation of the statements and the full manuscript among all authors with intermittent adaptation to comments (using a modified Delphi process). Levels of evidence and agreement were rated according to the GRADE system. Consensus was defined a priori as agreement by at least 75% of the authors. RESULTS: Key recommendations include the use of FMT in recurrent C. difficile infection characterised by at least two previous standard treatments without persistent cure, as well as its consideration in severe and severe-complicated C. difficile infection as an alternative to total colectomy in case of early failure of antimicrobial therapy. FMT in inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS) and metabolic syndrome should only be performed in research settings. CONCLUSIONS: Faecal microbiota transplantation or transfer is a promising treatment for a variety of diseases in which the intestinal microbiota is disturbed. For indications other than C. difficile infection, more evidence is needed before more concrete recommendations can be made.
引用
- König J, Siebenhaar A, Högenauer C, et al. Consensus report: faecal microbiota transfer - clinical applications and procedures. Aliment Pharmacol Ther. 2016. PMID: 27891639. doi:10.1111/apt.13868
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。